Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Akebia Therapeutics Inc (NASDAQ: AKBA) was $1.80 for the day, up 0.56% from the previous closing price of $1.79. In other words, the price has increased by $0.56 from its previous closing price. On the day, 1.33 million shares were traded. AKBA stock price reached its highest trading level at $1.84 during the session, while it also had its lowest trading level at $1.77.
Ratios:
Our analysis of AKBA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.21 and its Current Ratio is at 1.52.
On August 28, 2023, H.C. Wainwright Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $3.75.
Piper Sandler Upgraded its Neutral to Overweight on May 31, 2023, whereas the target price for the stock was revised from $2 to $4.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 13 ’24 when Hadas Nicole R. sold 12,016 shares for $1.26 per share. The transaction valued at 15,140 led to the insider holds 651,243 shares of the business.
Dahan Michel sold 34,840 shares of AKBA for $43,898 on May 13 ’24. The SVP, Chief Operating Officer now owns 672,092 shares after completing the transaction at $1.26 per share. On Feb 29 ’24, another insider, Dahan Michel, who serves as the SVP, Chief Operating Officer of the company, sold 8,661 shares for $1.58 each. As a result, the insider received 13,684 and left with 706,932 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AKBA now has a Market Capitalization of 392725760 and an Enterprise Value of 461904160. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.22. Its current Enterprise Value per Revenue stands at 2.719 whereas that against EBITDA is 104.74.
Stock Price History:
Over the past 52 weeks, AKBA has reached a high of $2.48, while it has fallen to a 52-week low of $0.80. The 50-Day Moving Average of the stock is 18.35%, while the 200-Day Moving Average is calculated to be 27.99%.
Shares Statistics:
AKBA traded an average of 1.82M shares per day over the past three months and 2947350 shares per day over the past ten days. A total of 218.18M shares are outstanding, with a floating share count of 207.21M. Insiders hold about 5.03% of the company’s shares, while institutions hold 24.82% stake in the company. Shares short for AKBA as of 1730332800 were 14835319 with a Short Ratio of 8.16, compared to 1727654400 on 18803189. Therefore, it implies a Short% of Shares Outstanding of 14835319 and a Short% of Float of 7.13.
